TABLE III.
Progression of Illness for BeS Versus CBD Subjects, Never Smokers Only
| Average change per year |
Average measure 10 years after first exposure |
Average measure 30 years after first exposure |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| BeS | CBD | P-valuea | BeS | CBD | P-valuea | BeS | CBD | P-valuea | |
| Pulmonary function | |||||||||
| FVC (L) | −0.02 | −0.03 | 4.82 | 4.80 | 4.37 | 4.20 | |||
| FEV1 (L) | −0.02 | −0.02 | 3.77 | 3.65 | 3.35 | 3.29 | |||
| FEV1/FVC | −0.16 | 0.04 | <0.05 | 79.4 | 77.1 | 76.3 | 78.0 | ||
| TLC (L) | 0.03 | 0.01 | <0.1 | 6.42 | 6.53 | 6.98 | 6.67 | <0.1 | |
| DLCO (ml/min/mm Hg) | −0.69 | −0.74 | 44.8 | 43.3 | 30.9 | 28.5 | <0.05 | ||
| Exercise physiology | |||||||||
| Maximum workload (W) | 0.13 | −0.73 | 197.9 | 202.6 | 200.6 | 188.1 | |||
| VO2 at maximal exercise (L/min) | −0.01 | −0.01 | 2.44 | 2.35 | 2.15 | 2.08 | |||
| PaO2 at rest (mm Hg) | −0.03 | −0.18 | 77.9 | 78.0 | 77.2 | 74.5 | <0.1 | ||
| PaO2 at maximal exercise (mm Hg) | −0.19 | −0.37 | 83.6 | 85.0 | 79.9 | 77.5 | |||
| (A-a)PaO2 at rest (mm Hg) | −0.07 | 0.05 | 6.96 | 6.90 | 5.48 | 7.80 | <0.05 | ||
| (A-a) PaO2 at maximal exercise (mm Hg) | −0.01 | 0.05 | 11.3 | 11.8 | 11.1 | 12.7 | |||
| Blood and bronchoalveolar lavage fluid markers | |||||||||
| Peak blood BeLPT (SI) | −0.24b | −0.36b | 9.29 | 12.77 | 3.50 | 3.84 | |||
| Peak BAL BeLPT (SI) | −0.03b | −0.10b | 2.15 | 8.02 | <0.01 | 1.58 | 5.96 | <0.01 | |
| BAL lymphocyte (%) | −0.44 | −0.81 | <0.1 | 18.8 | 38.7 | <0.01 | 10.1 | 22.4 | <0.01 |
| WBC/CC | −0.35b | −0.60b | 20.2 | 30.3 | <0.01 | 12.5 | 16.6 | <0.05 | |
Tabled values are estimates obtained from mixed model analyses.
Results apply to white males aged 52, height of 68 inches, 1970s start of employment, in the nuclear weapons industry.
Estimates for individuals with other characteristics can be obtained by using covariate information in Table IV.
a
P-value for BeS versus CBD comparison.
b
Average slope between 10 and 40 years from first exposure.